Natural effector cells in patients with acute myeloid leukemia treated with the immunomodulator linomide after autologous bone marrow transplantation

European Journal of Haematology

Volumn 63, Issue 4, 1999, Pages 251-258

  Hokland, M ^d   Jorgensen H ^a   Holm, Mette Skov ^a   Simonsson, Bengt ^b   Nilsson, Bo ^c   Bengtsson, Mats ^b   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Pharmacia and Upjohn   (Sweden)

^d Med Afd B Århus Amtssygehus ^*

Author keywords

Acute myeloid leukemia; Bone marrow transplantation; Immunotherapy; Linomide; Natural immunity

Indexed keywords

ROQUINIMEX;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0011929717     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01886.x     Document Type: Article

References (35)

1. 1. APPELBAUM FR. The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. CA Cancer J Clin 1996;46:142-64.
2. 2. HOROWITZ MM, GALE RP, SONDEL, PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
3. 3. LAURIA F, RASPADORI D, RONDELLI D, VENTURA MA, FOA R. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia 1994;8:724-8.
4. 4. GIRALT S, HESTER J, HUH Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86:4337-43.
5. 5. CASSILETH PA, ANDERSEN J, LAZARUS HM, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 1993;11:314-9.
6. 6. MANDELLI F, REES JK, GORIN NC, PRENTICE, HG. Post-remission treatment in acute myeloid leukemia: chemotherapy or autologous or allogeneic bone marrow transplantation. Haematologica 1990;75:203-11.
7. 7. PRENTICE HG, MACDONALD ID, HAMON MD. Understanding the mechanism of cure of acute myeloid leukemia by allogeneic bone marrow transplantation: toward the application of interleukin-2 in autologous bone marrow transplantation. J-Hematother 1994;3:47-50.
8. 8. ZITTON RA, MANDELLI F, WILLEMZE R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332:217-23.
9. 9. PARRADO A, RODRIGUEZ-FERNANDEZ JM, CASARES S, et al. Generation of LAK cells in vitro in patients with acute leukemia. Leukemia 1993;7:1344-8.
10. 10. BENYUNES MC, MASSUMOTO C, YORK A, et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993;12:159-63.
11. 11. ALMICI C, MANONI L, CARLO STELLA C, GARAU D, COTTAFAVI L, RIZZOLI V. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow. Bone Marrow Transplant 1995;16: 95-101.
12. 12. MELONI G, FOA R, VIGNETTI M, et al. Inlerleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994;84:2158-63.
13. 13. REITTIE JE, GOTTLIEB D, HESLOP H, et al. Endogenously generated activated killler cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989;73:1351-8.
14. 14. JØRGENSEN H, HOKLAND P, JENSEN T, BASSE P, HOKLAND M. Natural killer cells in peripheral blood after autologous bone marrow transplantation: a combined phenotypic and functional study. Nat Immun 1995;14:164-72.
15. 15. DE LAURENZI A, IUDICONE P, ZOLI V, et al. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects. J Hematother 1995;4: 113-20.
16. 16. LOTZE MT, MATORY YL, RAYNER AA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986;58:2764-72.
17. 17. SLAVIN S, ACKERSTEIN A, WEISS L, NAGLER A, OR R, NAPARSTEK E. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 1992;10:221-7.
18. 18. MARTENS AC, VAN BEKKUM DW, HAGENBEEK A. Minimal residual disease in leukemia: studies in an animal model for acute myclocytic leukemia (BNML). Int J Cell Cloning 1990;8:27-38.
19. 19. KALLAND T, ALM G, STALHANDSHE T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol 1985;134:3956-61.
20. 20. GONZALO JA, GONZALEZ GARCIA A, KALLAND T, HEDLUNG G, MARTINEZ C, KROEMER G. Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur J Immunol 1994;24:48-52.
21. 21. BENGTSSON M, SIMONSSON B, CARLSSON K, et al. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute mycloid leukemia. Transplantation 1992;53: 882-8.
22. 22. ARAD G, KATZENELLENBOGEN M, LEVY R, SLAVIN S, KAEMPFER R. Linomide, an immunomodulator that inhibits Thl cytokine gene expression. Int Immunol 1996;8:1603-7.
23. 23. HOKLAND M, JACOBSEN N, ELLEGAARD J, HOKLAND P. Natural killer function following allogeneic bone marrow transplantation. Very early re-emergence but strong dependence of cytomegalovirus infection. Transplantation 1988;45: 1080-4.
24. 24. NIELSEN B, HOKLAND P, ELLEGAARD J, HASSELBALCH H, HOKLAND M. Whole blood assay for NK activity in splenectomized and non-spleneclomized hairy cell leukemia patients during IFN-alpha-2b treatment, Leuk Res 1989;13:451-6.
25. 25. HALL SS. A commotion in the blood: Life, death, and the immune system. New York: Henry Holt and Co. Inc., 1997.
26. 26. BAER MR. Assessment of minimal residual disease in patients with acute leukemia, Curr Opin Oncol 1998; 10:17-22.
27. 27. RIVOLTINI L, LOFTUS DJ, BARRACCHINI K, et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J Immunol 1996,156:3882-91.
28. 28. MANDELLI F, VIGNETTI M, TOSTI S, ANDRIZZI C, FOA R, MELONI G. Interleukin 2 treatment in acute myclogenous leukemia. Stem Cells 1993;11:263-8.
29. 29. KLINGEMANN HG, EAVES CJ, BARNETT MJ, et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 1994;14:389-96.
30. 30. BAUMGARTEN E, SCHMID H, POHL U, et al. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia. Leukemia 1994;8:850-5.
31. 31. BASSE PH, NANNMARK U, JOHANSSON BR, HERBERMAN RB, GOLDFARB RH. Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J Natl Cancer Inst 1991;83:944-50.
32. 32. BENDALL LJ, KORTLEPEL K, GOTTLIEB DJ. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1. Leukemia 1995;9:677-84.
33. 33. BRUNE M, HELLSTRAND K, Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br J Haematol 1996;92:620-6.
34. 34. BRUNE M, HANSSON M, MELLQVIST UH, HERMODSSON S, HELLSTRAND K. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol 1996;57:312-9.
35. 35. HANSSON M, ASEA A, ERSSON U, HERMODSSON S, HELLSTRAND K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996;156:42-7.